Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.
Posted on: May 20, 2021 04:10PM
“In the phase II PATRICIA trial reported in the Journal of Clinical Oncology, Nancy U. Lin, MD, and colleagues found that pertuzumab plus high-dose trastuzumab produced central nervous system (CNS) objective responses and clinical benefit in 68% of patients with HER2-positive metastatic breast cancer with progressive brain metastases.“
Full article -
Report of study results (pdf file)